Showing 571-580 of 9539 results for "".
Part 1, 1726 nm lasers: Five dermatologists discuss the laser’s benefits and drawbacks for treating acne and other skin conditions
https://practicaldermatology.com/series/scientifically-speaking/1726-nm-lasers-five-dermatologists-discuss-the-lasers-benefits-and-drawbacks-for-treating-acne-and-other-skin-conditions/24339/Chapter 1 of 7: David Goldberg, MD, from New York, Emil Tanghetti, MD, from Sacramento, Jordan Wang, MD, from Philadelphia and New York and Naz Saedi, MD, from Philadelphia talk about how they have brought in the new 1726 nm wavelength lasers into their practices, what skin conditions it is most benDermwireTV: J&J Boosts Dermatology Pipeline; New Humira Biosimilar Launched
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-jj-boosts-dermatology-pipeline-new-humira-biosimilar-launched/24561/In this episode of DermwireTV, Johnson & Johnson makes a major acquisition to expand its dermatology treatment pipeline; the first high-concentration, citrate-free biosimilar to Humira is launched in the US; and in the C-Suite Chats feature, the CEO of Benev discusses the medical aesthetic markeFirst Medication for Severe Frostbite; Biosimilar to Humira with Interchangeability Status Approved; Two Late-Stage AD Candidates Advance
https://practicaldermatology.com/series/dermwire-tv/first-medication-for-severe-frostbite-biosimilar-to-humira-with-interchangeability-status-approved-two-late-stage-ad-candidates-advance/20267/In this episode of DermWireTV, the first medication to treat severe frostbite is approved by the FDA; the first high-concentration biosimilar to Humira with interchangeability status will soon be available in the US; and two companies with late-stage atopic dermatitis candidates provide key updates.How Early Experience With PDT Can Provide Career Pathways
https://practicaldermatology.com/series/pdt-in-practice/how-early-experience-with-pdt-can-provide-career-pathways/20212/Adam Friedman, MD, professor and chair of dermatology at George Washington University, discusses how early-career experience with photodynamic therapy, including exposure to doctor-mentors in the field, gave him professional skills and connections that prepared him for later-career opportunities.EBD Insights
https://practicaldermatology.com/conferences/maui-derm-2022/ebd-insights/20049/There are a number of new and reliable energy-based devices available. Michael H. Gold, MD discusses tried-and-true technologies as well as new and innovative devices that offer efficacious options on the market for a variety of dermatologic needs.DermWireTV: Arcutis Takes PASI HD; Galderma at Camp Wonder; Amgen Challenge; LaRoche-Posay Pride
https://practicaldermatology.com/topics/psoriasis/dermwiretv-arcutis-takes-pasi-hd-galderma-at-camp-wonder-amgen-challenge-laroche-posay-pride/19996/The PASI high discrimination or PASI-HD tool was developed by Arcutis Biotherapeutics in collaboration with a panel of psoriasis research experts. Led by Amgen, in partnership with the International Federation of Psoriasis Associations, the Understanding Psoriatic Disease Leveraging Insights for TreManaging Advanced Skin Cancers
https://practicaldermatology.com/conferences/aad-2021/managing-advanced-skin-cancers/19920/Treatment of advanced NMSC can be a challenge, but therapeutic options continue to expand. Todd Schlesinger, MD discusses real-world use of hedgehog inhibitors—including modified regimens and adjuvant use—and PD-1 inhibitors for advanced disease.Scientifically Speaking: Optimized Approaches to AK Management
https://practicaldermatology.com/topics/skin-cancer-photoprotection/scientifically-speaking-optimized-approaches-to-ak-management/19912/What's new in AK therapy? From a new, first-in-class molecule to updated approaches with long-standing treatments, the management of actinic keratosis continues to evolve. Scientifically Speaking host Joel L. Cohen, MD speaks with Neal Bhatia, MD, Michael H. Gold, MD, and George Martin, MD about theDermWireTV: Pulse's CellFX, Soliton's RAP Technology, Belotero Balance (+), Restylane Defyne, Eczema Costs
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-pulses-cellfx-solitons-rap-technology-belotero-balance-restylane-defyne-eczema-costs/19899/The FDA has cleared Pulse Biosciences’ CellFX system, and a commercial rollout will begin soon. There’s another new option for treatment for legs with FDA clearance of Soliton’s Rapid Acoustic Pulse technology for cellulite. For eight percent of Americans with atopic dermatitis, annual out of pocketPatient Assessment: A Key to AD Care
https://practicaldermatology.com/topics/atopic-dermatitis/patient-assessment-a-key-to-ad-care/19889/What is the Quality of Care in Atopic Dermatitis initiative, and why is it important? Dr. Stephan Weidinger shares his thoughts on the importance of this "impressive" program and offers suggestions to improve the assessment and care of patents with eczema.